Biomedical (ADVANCED)

Ended Definitive Contract Awarded Last action

Contract number
HHSO100201100012C
Awardee
Awarding agency
Obligated
$121,393,966

Award facts

Contract value 60% obligated
  • $121,393,965.87 Current, with exercised options
  • $203,202,473.87 Potential, with all options
Completion date 100% complete
Current and potential, with all options
Set-aside
No set-aside
Competition
Full and Open Competition · 4 offers Negotiated Proposal / Quote
Pricing
Cost Plus Fixed Fee
Place of performance
Rockville, MD 20850, USA

Award details come from SAM.gov/FPDS.

Transactions

Action Obligated Date
Other Administrative Action P00012 · Close contract and deobligate excess funds. The final invoice/voucher number E001045480 in the amount of $7,500,000 dated february 19, 2020, was made per the… -$53,543,659
Funding Only Action P00011 $0
Change Order 10 $0
Change Order 9 · Aspr 2016 $0
Funding Only Action 8 $7,676,744
Change Order 7 $0
Exercise an Option 6 · Aspr 2014 $70,000,000
Change Order 5 · To revise article B.2. To 1)extend the period of performance, and reallocate funds between clins, and 2)revise article G.3. Key personnel. $0
Other Administrative Action 4 $0
Other Administrative Action 3 $0
Other Administrative Action 2 · To revise article B.2. Contract line item numbers to reallocate funds between clins. $0
Other Administrative Action 1 · To revise article G.3. Key personnel and article G.4. Invoice submission. $0
Original award $97,260,881
Show all 13

About this award

Written by GovTribe AI ·

This is a $203.2 million cost-plus-fixed-fee definitive contract awarded by the Department of Health and Human Services' Office of the Assistant Secretary for Preparedness and Response to Novavax Inc. for the advanced development of recombinant influenza vaccine products and manufacturing capabilities. The contract, which has no set-aside designation, runs through February 2020. Novavax is a biotechnology company that develops and produces recombinant protein nanoparticle vaccines. Through this contract, Novavax is providing COVID-19 vaccine research, development, and manufacturing services. Novavax has also received a $45.7 million definitive contract from the Department of the Army to support vaccine development and production related to the COVID-19 response, as well as Indefinite Delivery Vehicle (IDV) contracts from the Centers for Disease Control and Prevention to provide adult and pediatric COVID-19 vaccines, and a Federal Supply Schedule contract with the Department of Veterans Affairs for pharmaceuticals and hematology products.

Quick answers

Who was awarded contract HHSO100201100012C?

HHSO100201100012C was awarded to Novavax Inc. by Office of the Assistant Secretary for Preparedness and Response (Department of Health and Human Services) on February 24, 2011.

How much is contract HHSO100201100012C worth?

The government has obligated $121,393,966 on HHSO100201100012C. Its potential value, with all options, is $203,202,474.

Was contract HHSO100201100012C competed?

The extent of competition for HHSO100201100012C was full and open competition. The government received 4 offers.

On GovTribe

See this award's full record

  • Every transaction and funding action
  • The awardee's other awards and teaming partners
  • Similar awards and recompete opportunities
  • Ask GovTribe AI about this award
Try for free Login